Abstract
From uncertain beginnings over four decades ago, heart transplantation is now the definitive therapy for end-stage heart failure. This review will attempt to comprehensively cover the broad gamut of anesthetic, hemodynamic, antimicrobial, immunosuppressive and hemostatic agents used by the cardiothoracic anesthesiologist in the perioperative management of patients with endstage heart disease.
Keywords: Heart failure, heart transplantation, volatile anesthetics, opioids, benzodiazepines, immunosuppresants
Current Clinical Pharmacology
Title:Anesthetic Pharmacology and Perioperative Considerations for Heart Transplantation
Volume: 10 Issue: 1
Author(s): Harish Ramakrishna, Kent H. Rehfeldt and Octavio E. Pajaro
Affiliation:
Keywords: Heart failure, heart transplantation, volatile anesthetics, opioids, benzodiazepines, immunosuppresants
Abstract: From uncertain beginnings over four decades ago, heart transplantation is now the definitive therapy for end-stage heart failure. This review will attempt to comprehensively cover the broad gamut of anesthetic, hemodynamic, antimicrobial, immunosuppressive and hemostatic agents used by the cardiothoracic anesthesiologist in the perioperative management of patients with endstage heart disease.
Export Options
About this article
Cite this article as:
Ramakrishna Harish, Rehfeldt H. Kent and Pajaro E. Octavio, Anesthetic Pharmacology and Perioperative Considerations for Heart Transplantation, Current Clinical Pharmacology 2015; 10 (1) . https://dx.doi.org/10.2174/1574884709666140212104958
DOI https://dx.doi.org/10.2174/1574884709666140212104958 |
Print ISSN 1574-8847 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3938 |
Related Articles
-
Human Imprinting Anomalies in Fetal and Childhood Growth Disorders: Clinical Implications and Molecular Mechanisms
Current Pharmaceutical Design Potential Benefits and Limits of Psychopharmacological Therapies in Pervasive Developmental Disorders
Current Clinical Pharmacology New Player on An Old Field; the Keap1/Nrf2 Pathway as a Target for Treatment of Type 2 Diabetes and Metabolic Syndrome
Current Diabetes Reviews Protein Kinase C as a Drug Target Implications for Drug or Diet Prevention and Treatment of Cancer
Current Drug Targets Curcumin as an Adjuvant to Breast Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry A Critical Approach of Guideline Therapeutic Recommendations for NAFLD
Current Vascular Pharmacology Hypertension and Counter-Hypertension Mechanisms in Giraffes
Cardiovascular & Hematological Disorders-Drug Targets The Prodigiosins: A New Family of Anticancer Drugs
Current Cancer Drug Targets Impact of Oral 1,25-Dihydroxy Vitamin D (Calcitriol) Replacement Therapy on Coronary Artery Risk Factors in Type 2 Diabetic Patients
Endocrine, Metabolic & Immune Disorders - Drug Targets Diabetic Cardiomyopathy and Oxidative Stress: Role of Antioxidants
Cardiovascular & Hematological Agents in Medicinal Chemistry Induced Adaptive Resistance to Oxidative Stress in the CNS: A Discussion on Possible Mechanisms and Their Therapeutic Potential
Current Drug Metabolism New Assay for Old Markers-Plasma Beta Amyloid of Mild Cognitive Impairment and Alzheimer’s Disease
Current Alzheimer Research Metabolism of Nucleosides and Nucleotides Prodrugs
Current Pharmaceutical Design Episcopic 3D Imaging Methods: Tools for Researching Gene Function
Current Genomics Effects of Oral L-Citrulline Supplementation on Lipoprotein Oxidation and Endothelial Dysfunction in Humans with Vasospastic Angina
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Bacterial Toxins: Potential Weapons Against HIV Infection
Current Pharmaceutical Design Protein Kinase C Isozyme Selective Peptides - A Current View of What they Tell Us About Location and Function of Isozymes in the Heart
Current Pharmaceutical Design Identification and Determination of Potential Impurities Present in the Acyclovir Drug Substance by GC-MS
Current Pharmaceutical Analysis The Interaction Between Gender and Diabetes Mellitus in the Coronary Heart Disease Risk
Current Pharmaceutical Design OX40:OX40L Axis: Emerging Targets for Immunotherapy of Human Disease
Current Immunology Reviews (Discontinued)